Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fordyce

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of the Neurological Sciences|December 1, 1992
Expression of CD45RC and Ia antigen in the spinal cord in acute experimental allergic encephalomyelitis: an immunocytochemical and flow cytometric studyP A McCombe, B W Fordyce, J de Jersey, et al.
Pain|June 1, 1981
Pain complaint--exercise performance relationship in chronic painW Fordyce, R McMahon, G Rainwater, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 2, 2012
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelopeCraig S Pace, Marshall W Fordyce, David Franco, et al.
Cancer|February 1, 1994
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugatesM E Schott, J Schlom, K Siler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyFrank A Post, Pablo Tebas, Amanda Clarke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 26, 2017
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuationLouis S Matza, Karen C Chung, Katherine J Kim, et al.
HIV Clinical Trials|October 29, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patientsRima Kulkarni, Michael E Abram, Damian J McColl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsPeter J Ruane, Edwin DeJesus, Daniel Berger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 19, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsNathan Clumeck, Jean-Michel Molina, Keith Henry, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of the Neurological Sciences|December 1, 1992
Expression of CD45RC and Ia antigen in the spinal cord in acute experimental allergic encephalomyelitis: an immunocytochemical and flow cytometric studyP A McCombe, B W Fordyce, J de Jersey, et al.
Pain|June 1, 1981
Pain complaint--exercise performance relationship in chronic painW Fordyce, R McMahon, G Rainwater, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 2, 2012
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelopeCraig S Pace, Marshall W Fordyce, David Franco, et al.
Cancer|February 1, 1994
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugatesM E Schott, J Schlom, K Siler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyFrank A Post, Pablo Tebas, Amanda Clarke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 26, 2017
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuationLouis S Matza, Karen C Chung, Katherine J Kim, et al.
HIV Clinical Trials|October 29, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patientsRima Kulkarni, Michael E Abram, Damian J McColl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsPeter J Ruane, Edwin DeJesus, Daniel Berger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 19, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsNathan Clumeck, Jean-Michel Molina, Keith Henry, et al.
Pageof 3